Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Pertuzumab

What is Pertuzumab?

CAS No: 380610-27-5

Pertuzumab is a chemically defined substance encountered in pharmaceutical manufacturing whose health-based exposure limit derivation requires integration of pharmacological, toxicokinetic, and general toxicological data to identify the most relevant point of departure. The quality and completeness of the toxicological database for Pertuzumab directly influences the magnitude of uncertainty factors applied and the confidence in the resulting PDE value. Periodic review of new published data and post-market clinical safety signals ensures that the OEL for Pertuzumab remains protective as scientific knowledge develops.

Reproductive and developmental toxicity findings for Pertuzumab receive an additional severity factor consideration in PDE derivation, because pharmaceutical patient populations frequently include women of childbearing potential and, in some indications, pregnant patients.

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Pertuzumab is a biologic or macromolecular substance based on its name. Its assessment may require consideration of the relevant biological activity and the available non-clinical, clinical, or other safety information. A substance-specific toxicological review helps clarify potential exposure concerns and the appropriate scope of risk management.

A PDE or ADE sets a health-based limit on daily exposure to Pertuzumab from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

For Pertuzumab, the assessment can consider the tasks and conditions that may influence exposure, including material charging, transfer, sampling, equipment maintenance, and cleaning. The form handled, potential for dust or aerosol generation, process containment, and duration of work can affect the risk-management approach. Task-specific information helps connect the toxicological assessment with practical workplace controls.

If Pertuzumab is a substance with relevant therapeutic-use information, dose information may contribute context to the assessment, but it does not by itself establish a PDE, ADE, or OEL. The evaluator must consider the quality and relevance of the full evidence package, including critical effects and route of exposure. Any use of dose information should be scientifically justified and clearly documented.

Where relevant information is available, the pharmacological activity of Pertuzumab can help identify effects that may be important for a health-based exposure assessment. Evaluators consider the reliability and relevance of the evidence rather than assuming that therapeutic activity alone determines an exposure limit. The selected critical effect, dose-response basis, and uncertainty factors should be explained in the assessment.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Pertuzumab in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

Handling risks for Pertuzumab should be evaluated against the actual activities and exposure pathways involved, which may include formulation, filling, transfer, sampling, and cleaning where applicable. The review can consider the substance's properties, available hazard information, process conditions, containment, and work practices. The resulting recommendations should be proportionate to the evidence and the specific operations being assessed.

A toxicological assessment of Pertuzumab organizes the available evidence about potential health hazards and the uncertainty around that evidence. The findings can support scientifically justified exposure limits and proportionate controls for manufacturing, sampling, transfer, and cleaning. The assessment should distinguish established findings from assumptions and identify any data gaps that affect confidence in the conclusions.

For Pertuzumab, uncertainty factors may address differences between test species and humans, variability among people, study duration, study quality, and limitations in the available dataset. The choice and magnitude of each factor depend on the evidence and the assessment method. A defensible report documents the rationale for each factor so the derivation can be reviewed and reproduced.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Pertuzumab to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo